Welcome to our dedicated page for MNK news (Ticker: MNK), a resource for investors and traders seeking the latest updates and insights on MNK stock.
The MNK news page on Stock Titan aggregates company-issued updates and media coverage related to Mallinckrodt plc and its subsequent branded therapeutics identity, Keenova Therapeutics. Recent press releases describe Mallinckrodt as a global specialty pharmaceutical company with a Brands business focused on autoimmune and rare diseases and a Par Health business that includes generic drugs, sterile injectables and active pharmaceutical ingredients.
News items for MNK include announcements on corporate transactions, such as the completion of the merger between Mallinckrodt and Endo, Inc., and the spin-off of the combined generics and sterile injectables businesses under the Par Health name. These releases also explain that, moving ahead, Mallinckrodt will be known as Keenova Therapeutics, a branded therapeutics company focused on helping patients with rare or unaddressed conditions.
Investors and followers of MNK can find updates on financial results, including quarterly net sales and segment performance for Specialty Brands, Generics and Sterile Injectables as reported by the company. Other news covers developments in key branded products, such as Acthar Gel and XIAFLEX, as well as communications about clinical and medical affairs activities, including data presentations related to TERLIVAZ for hepatorenal syndrome.
Additional coverage includes leadership and governance announcements, such as board appointments and executive changes, along with guidance and commentary on the company’s strategy around its Brands and Par Health businesses. For users tracking MNK, this news feed provides a central view of the company’s own disclosures on its therapeutic focus, portfolio evolution, corporate structure and branded transition to Keenova Therapeutics.
Keenova Therapeutics (formerly Mallinckrodt, NYSE: MNK) completed the spin-off of Par Health on Nov 10, 2025 and rebranded to focus on branded therapeutics for rare and unmet conditions.
The company reported a 2024 pro-forma combined revenue of $1.7 billion, employs >1,600 people, and lists flagship products Acthar Gel and XIAFLEX. Keenova is headquartered in Dublin with a U.S.-focused commercial and manufacturing footprint.
The company intends to pursue a NYSE listing in 2026 and expects to conduct a public offering to facilitate the listing, subject to board approval and other conditions.
Mallinckrodt (NYSE:MNK) will present four posters, including one AASLD Poster of Distinction, at The Liver Meeting (AASLD) in Washington, D.C., Nov 7–11, 2025.
Presentations focus on hepatorenal syndrome (HRS) and TERLIVAZ (terlipressin), the first FDA-approved therapy to improve kidney function in adults with HRS‑AKI. Session: Portal Hypertension and Other Complications of Cirrhosis on Nov 8, 2025. Poster numbers: #2285 (Distinction), #2401, #2315, #2380. Key prescribing notes: patients with serum creatinine >5 mg/dL are unlikely to benefit. Important safety: boxed warning for serious or fatal respiratory failure; contraindications include hypoxia and active ischemia.
Mallinckrodt (NYSE:MNK) will report its third quarter 2025 financial results on Monday, November 10, 2025 before market open.
The company will host a conference call the same day at 8:00 a.m. ET with an audio webcast available in the Investor Relations section at ir.mallinckrodt.com under Events & Presentations. Participants can register to receive a dial-in number and personalized PIN; attendees are advised to join 10 minutes early. A replay of the webcast will be available after the event.
Mallinckrodt (NYSE:MNK) announced support for the inaugural Hepatorenal Syndrome (HRS) Awareness Day, established by the American Liver Foundation and observed annually on October 14 during National Liver Awareness Month.
The initiative aims to raise awareness, promote early detection and treatment, and share patient experiences. HRS is described in two types: HRS‑AKI (rapid, often requiring hospitalization) and HRS‑CKD (slower progression). The release states HRS affects more than 60,000 Americans annually (~0.01% of the U.S. population) and that hospitalization rates for HRS are increasing. Company and ALF leaders commented on the need to improve visibility and treatment options for patients.
Mallinckrodt (NYSE:MNK) has published findings from a cross-sectional physician survey and medical chart review regarding Acthar® Gel treatment in patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). The study, published in Open Access Rheumatology: Research and Reviews, demonstrated that some patients experienced positive treatment outcomes including reduced symptoms, decreased pain, improved physical function, and reduced corticosteroid use.
Acthar Gel, an FDA-approved complex mixture of ACTH analogs and pituitary peptides, is indicated for treating various autoimmune disorders and inflammatory conditions. The research provides valuable real-world data on the medication's clinical application and effectiveness in treating these complex arthritic conditions.
Mallinckrodt (MNK) has appointed Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025. Stamoulis, currently EVP and CFO at Incyte, will succeed Bryan Reasons, who is departing to pursue other opportunities.
With approximately 30 years of biotechnology industry experience, Stamoulis brings extensive expertise in strategy, finance, and corporate development. Her appointment follows Mallinckrodt's recent merger with Endo, marking a significant transformation period for the company. In her new role, she will oversee the finance organization and lead corporate development initiatives.
Prior to Incyte, Stamoulis held leadership positions at Unum Therapeutics, Vertex Pharmaceuticals, and served as Managing Director at Citigroup's Investment Banking division. She holds two BS degrees and an MBA from MIT.
Mallinckrodt (MNK) reported Q2 2025 financial results and provided guidance following its merger with Endo. Legacy Mallinckrodt achieved net sales of $485.1M (down 5.7% YoY, but up 8.5% excluding Therakos divestiture) and net income of $2.4M. Legacy Endo reported flat revenues of $447.8M with a net loss of $59.6M.
Key highlights include Acthar Gel's highest growth in over a decade (up 48.8% to $175.1M) and XIAFLEX's 9.4% growth to $138.6M. The combined company projects 2025 net sales of $3.57B-$3.62B and adjusted EBITDA of $1.10B-$1.13B. The planned spin-off of Par Health remains on track for Q4 2025, with expected net sales of $1.72B-$1.75B.
The company raised Acthar Gel's 2025 growth guidance to 20-30% from high-single digits and reaffirmed XIAFLEX's high-single digit growth outlook.Mallinckrodt (NYSE:MNK) has appointed Leslie Donato to its Board of Directors, completing its nine-member board following the recent merger with Endo, Inc. As former Executive Vice President and Chief Strategy Officer of Cencora, Donato brings over 30 years of healthcare industry experience and a track record of executing successful M&A strategies, having deployed over $10 billion in capital at Cencora and contributing to a 130% market cap increase over five years.
The appointment follows Mallinckrodt's August 1, 2025 merger with Endo, creating a global therapeutics leader. The board now comprises four members from each legacy company, with Donato jointly selected as the ninth member. Her extensive experience includes leadership roles at Bayer Healthcare Pharmaceuticals and McKinsey & Company.
Mallinckrodt (NYSE:MNK) and Endo have completed their merger to create a global therapeutics leader. Under the deal terms, Endo shareholders received $100 million in cash and will own 49.9% of Mallinckrodt, while pre-transaction Mallinckrodt shareholders retain 50.1% ownership.
The merger includes plans to spin off their combined generics and sterile injectables business (Par Health) as an independent company by Q4 2025. The company expects to achieve $150 million in annual pre-tax synergies by Year 3, with $75 million in the first year. A $1.35 billion secured credit facility was established to refinance debt and fund the transaction.
Post spin-off, the branded therapeutics company will seek NYSE listing. Siggi Olafsson continues as CEO, with Paul Efron serving as Board Chair of the combined entity.
Mallinckrodt (NYSE:MNK), a global specialty pharmaceutical company, has scheduled its second quarter 2025 financial results announcement for Wednesday, August 6, 2025. The company will host an investor conference call at 8:30 a.m. ET.
Investors can participate through multiple channels, including a live dial-in registration system and an audio-only webcast. The presentation will also be accessible through Mallinckrodt's Investor Relations website.